What are the Nutritional Supplements to Treat Hair Loss
Hot subjects in the therapy of alopecia areata were discussed in Mesinkovska's presentation, including vaccinations and viruses, JAK inhibitors, dupilumab, minoxidil, and what is in the works.
The association between
alopecia areata and COVID-19, as well as the COVID-19 vaccine and boosters,
were the topics of Mesinkovska's
opening remarks. In other instances, many of Mesinkovska's patients developed
moderate COVID-19 cases followed by alopecia areata totalis. Additionally,
after receiving the COVID-19 vaccination, several patients with alopecia areata
who had previously been stable or making progress started losing their hair
once more. Mesinkovska emphasized that while she does not think this should be
a justification for forgoing a COVID-19 vaccination or booster, physicians
should take the side effects into consideration and discuss them with their
patients.
For the treatment of
adult alopecia
areata, doctors now have a new JAK inhibitor to choose from: baricitinib
(Olumiant; Eli Lily). Clinical trials for deuruxolitinibCTP 543, ritlecitinib,
and delgotcitinib are now being conducted for alopecia areata. Mesinkovska
advised doctors to address adverse occurrences with their patients and to be aware
of the black box warnings for JAK inhibitors.
Dupilumab also has
promising potential as a therapy for alopecia areata. IL-4 and IL-13 antagonist
dupilumab is presently licensed to treat both adult and pediatric atopic
dermatitis. For individuals with alopecia areata who are hesitant to begin JAK
inhibitors or for young patients, minoxidil
is still an effective treatment choice. Minoxidil side effects include lower
limb edema, postural hypotension, and hypertrichosis.
Finally, the
sphingosine 1-phosphate receptor modulator etrasimod is a potential treatment
for alopecia areata. It is a once-daily oral pill with a history of
eosinophilic esophagitis, Crohn's disease, and ulcerative colitis.
Comments
Post a Comment